

Mariana ChÃ¡vez-MacGregor

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/5836172/publications.pdf>

Version: 2024-02-01

116
papers

7,327
citations

94269

37
h-index

58464

82
g-index

117
all docs

117
docs citations

117
times ranked

10034
citing authors

| # | ARTICLE | IF | CITATIONS |
|----|--|-----|-----------|
| 1 | Improved Axillary Evaluation Following Neoadjuvant Therapy for Patients With Node-Positive Breast Cancer Using Selective Evaluation of Clipped Nodes: Implementation of Targeted Axillary Dissection. <i>Journal of Clinical Oncology</i> , 2016, 34, 1072-1078. | 0.8 | 626 |
| 2 | Beta-Blocker Use Is Associated With Improved Relapse-Free Survival in Patients With Triple-Negative Breast Cancer. <i>Journal of Clinical Oncology</i> , 2011, 29, 2645-2652. | 0.8 | 400 |
| 3 | Society of Surgical Oncologyâ€“American Society for Radiation Oncology Consensus Guideline on Margins for Breast-Conserving Surgery With Whole-Breast Irradiation in Stages I and II Invasive Breast Cancer. <i>Journal of Clinical Oncology</i> , 2014, 32, 1507-1515. | 0.8 | 369 |
| 4 | Society of Surgical Oncologyâ€“American Society for Radiation Oncology Consensus Guideline on Margins for Breast-Conserving Surgery With Whole-Breast Irradiation in Stages I and II Invasive Breast Cancer. <i>International Journal of Radiation Oncology Biology Physics</i> , 2014, 88, 553-564. | 0.4 | 364 |
| 5 | Society of Surgical Oncologyâ€“American Society for Radiation Oncology Consensus Guideline on Margins for Breast-Conserving Surgery With Whole-Breast Irradiation in Stages I and II Invasive Breast Cancer. <i>Annals of Surgical Oncology</i> , 2014, 21, 704-716. | 0.7 | 348 |
| 6 | Delayed Initiation of Adjuvant Chemotherapy Among Patients With Breast Cancer. <i>JAMA Oncology</i> , 2016, 2, 322. | 3.4 | 267 |
| 7 | Effect of zoledronic acid on disseminated tumour cells in women with locally advanced breast cancer: an open label, randomised, phase 2 trial. <i>Lancet Oncology</i> , The, 2010, 11, 421-428. | 5.1 | 253 |
| 8 | Clinical Impact of Delaying Initiation of Adjuvant Chemotherapy in Patients With Breast Cancer. <i>Journal of Clinical Oncology</i> , 2014, 32, 735-744. | 0.8 | 237 |
| 9 | Society of Surgical Oncologyâ€“American Society for Radiation Oncologyâ€“American Society of Clinical Oncology Consensus Guideline on Margins for Breast-Conserving Surgery With Whole-Breast Irradiation in Ductal Carcinoma In Situ. <i>Journal of Clinical Oncology</i> , 2016, 34, 4040-4046. | 0.8 | 211 |
| 10 | Trastuzumab-Related Cardiotoxicity Among Older Patients With Breast Cancer. <i>Journal of Clinical Oncology</i> , 2013, 31, 4222-4228. | 0.8 | 207 |
| 11 | Epidemiology, biology, and treatment of triple-negative breast cancer in women of African ancestry. <i>Lancet Oncology</i> , The, 2014, 15, e625-e634. | 5.1 | 186 |
| 12 | Society of Surgical Oncologyâ€“American Society for Radiation Oncologyâ€“American Society of Clinical Oncology Consensus Guideline on Margins for Breast-Conserving Surgery with Whole-Breast Irradiation in Ductal Carcinoma In Situ. <i>Annals of Surgical Oncology</i> , 2016, 23, 3801-3810. | 0.7 | 176 |
| 13 | Targeting the PI3K/AKT/mTOR Pathway for the Treatment of Mesenchymal Triple-Negative Breast Cancer. <i>JAMA Oncology</i> , 2017, 3, 509. | 3.4 | 154 |
| 14 | Validation Study of the American Joint Committee on Cancer Eighth Edition Prognostic Stage Compared With the Anatomic Stage in Breast Cancer. <i>JAMA Oncology</i> , 2018, 4, 203. | 3.4 | 152 |
| 15 | A Clinical Feasibility Trial for Identification of Exceptional Responders in Whom Breast Cancer Surgery Can Be Eliminated Following Neoadjuvant Systemic Therapy. <i>Annals of Surgery</i> , 2018, 267, 946-951. | 2.1 | 147 |
| 16 | Phase II trial of AKT inhibitor MK-2206 in patients with advanced breast cancer who have tumors with PIK3CA or AKT mutations, and/or PTEN loss/PTEN mutation. <i>Breast Cancer Research</i> , 2019, 21, 78. | 2.2 | 141 |
| 17 | Society of Surgical Oncologyâ€“American Society for Radiation Oncologyâ€“American Society of Clinical Oncology Consensus Guideline on Margins for Breast-Conserving Surgery With Whole-Breast Irradiation in Ductal Carcinoma in Situ. <i>Practical Radiation Oncology</i> , 2016, 6, 287-295. | 1.1 | 135 |
| 18 | Selection of Optimal Adjuvant Chemotherapy and Targeted Therapy for Early Breast Cancer: ASCO Clinical Practice Guideline Focused Update. <i>Journal of Clinical Oncology</i> , 2018, 36, 2433-2443. | 0.8 | 131 |

| # | ARTICLE | IF | CITATIONS |
|----|---|-----|-----------|
| 19 | Nodal Status and Clinical Outcomes in a Large Cohort of Patients With Triple-Negative Breast Cancer. <i>Journal of Clinical Oncology</i> , 2011, 29, 2628-2634. | 0.8 | 128 |
| 20 | cMET and Phospho-cMET Protein Levels in Breast Cancers and Survival Outcomes. <i>Clinical Cancer Research</i> , 2012, 18, 2269-2277. | 3.2 | 108 |
| 21 | Validation and Development of a Modified Breast Graded Prognostic Assessment As a Tool for Survival in Patients With Breast Cancer and Brain Metastases. <i>Journal of Clinical Oncology</i> , 2015, 33, 2239-2245. | 0.8 | 104 |
| 22 | The Neo-Bioscore Update for Staging Breast Cancer Treated With Neoadjuvant Chemotherapy. <i>JAMA Oncology</i> , 2016, 2, 929. | 3.4 | 94 |
| 23 | Cardiac Monitoring During Adjuvant Trastuzumab-Based Chemotherapy Among Older Patients With Breast Cancer. <i>Journal of Clinical Oncology</i> , 2015, 33, 2176-2183. | 0.8 | 93 |
| 24 | Cardiotoxicity and Cardiac Monitoring Among Chemotherapy-Treated Breast Cancer Patients. <i>JACC: Cardiovascular Imaging</i> , 2018, 11, 1084-1093. | 2.3 | 93 |
| 25 | Male breast cancer according to tumor subtype and race. <i>Cancer</i> , 2013, 119, 1611-1617. | 2.0 | 91 |
| 26 | Impact of Time from Completion of Neoadjuvant Chemotherapy to Surgery on Survival Outcomes in Breast Cancer Patients. <i>Annals of Surgical Oncology</i> , 2016, 23, 1515-1521. | 0.7 | 86 |
| 27 | Incorporating Tumor Characteristics to the American Joint Committee on Cancer Breast Cancer Staging System. <i>Oncologist</i> , 2017, 22, 1292-1300. | 1.9 | 84 |
| 28 | Overall survival differences between patients with inflammatory and noninflammatory breast cancer presenting with distant metastasis at diagnosis. <i>Breast Cancer Research and Treatment</i> , 2015, 152, 407-416. | 1.1 | 68 |
| 29 | Selection of Optimal Adjuvant Chemotherapy and Targeted Therapy for Early Breast Cancer: ASCO Guideline Update. <i>Journal of Clinical Oncology</i> , 2021, 39, 685-693. | 0.8 | 66 |
| 30 | Age and Survival Estimates in Patients Who Have Node-Negative T1ab Breast Cancer by Breast Cancer Subtype. <i>Clinical Breast Cancer</i> , 2011, 11, 325-331. | 1.1 | 62 |
| 31 | Nomograms for Predicting Axillary Response to Neoadjuvant Chemotherapy in Clinically Node-Positive Patients with Breast Cancer. <i>Annals of Surgical Oncology</i> , 2016, 23, 3501-3509. | 0.7 | 54 |
| 32 | Postmenopausal Breast Cancer Risk and Cumulative Number of Menstrual Cycles. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2005, 14, 799-804. | 1.1 | 53 |
| 33 | Implementation of the American College of Surgeons Oncology Group Z1071 Trial Data in Clinical Practice: Is There a Way Forward for Sentinel Lymph Node Dissection in Clinically Node-Positive Breast Cancer Patients Treated with Neoadjuvant Chemotherapy?. <i>Annals of Surgical Oncology</i> , 2014, 21, 2468-2473. | 0.7 | 53 |
| 34 | Frequency of mesenchymal-epithelial transition factor gene (<i>MET</i>) and the catalytic subunit of phosphoinositide 3-kinase (<i>PIK3CA</i>) copy number elevation and correlation with outcome in patients with early stage breast cancer. <i>Cancer</i> , 2013, 119, 7-15. | 2.0 | 49 |
| 35 | Comparative Effectiveness of an mTOR-Based Systemic Therapy Regimen in Advanced, Metaplastic and Nonmetaplastic Triple-Negative Breast Cancer. <i>Oncologist</i> , 2018, 23, 1300-1309. | 1.9 | 46 |
| 36 | Pathologic complete response in breast cancer patients receiving anthracycline and taxane based neoadjuvant chemotherapy. <i>Cancer</i> , 2010, 116, 4168-4177. | 2.0 | 44 |

| # | ARTICLE | IF | CITATIONS |
|----|--|-----|-----------|
| 37 | Bioscore: A Staging System for Breast Cancer Patients that Reflects the Prognostic Significance of Underlying Tumor Biology. <i>Annals of Surgical Oncology</i> , 2017, 24, 3502-3509. | 0.7 | 44 |
| 38 | Personalized Prognostic Prediction Models for Breast Cancer Recurrence and Survival Incorporating Multidimensional Data. <i>Journal of the National Cancer Institute</i> , 2017, 109, . | 3.0 | 42 |
| 39 | Chemotherapy and Targeted Therapy for Patients With Human Epidermal Growth Factor Receptor 2â€“Negative Metastatic Breast Cancer That is Either Endocrine-Pretreated or Hormone Receptorâ€“Negative: ASCO Guideline Update. <i>Journal of Clinical Oncology</i> , 2021, 39, 3938-3958. | 0.8 | 40 |
| 40 | The next era of treatment for hormone receptor-positive, HER2-negative advanced breast cancer: Triplet combination-based endocrine therapies. <i>Cancer Treatment Reviews</i> , 2017, 61, 53-60. | 3.4 | 39 |
| 41 | Lifetime cumulative number of menstrual cycles and serum sex hormone levels in postmenopausal women. <i>Breast Cancer Research and Treatment</i> , 2008, 108, 101-112. | 1.1 | 38 |
| 42 | The Impact of Paravertebral Block Analgesia on Breast Cancer Survival After Surgery. <i>Regional Anesthesia and Pain Medicine</i> , 2016, 41, 696-703. | 1.1 | 38 |
| 43 | Randomized Clinical Trials and Observational Studies: Is There a Battle?. <i>Journal of Clinical Oncology</i> , 2016, 34, 772-773. | 0.8 | 38 |
| 44 | DCIS Margins and Breast Conservation: MD Anderson Cancer Center Multidisciplinary Practice Guidelines and Outcomes. <i>Journal of Cancer</i> , 2017, 8, 2653-2662. | 1.2 | 38 |
| 45 | Complications after breast cancer surgery in patients treated with concomitant preoperative chemoradiation: a caseâ€“control analysis. <i>Breast Cancer Research and Treatment</i> , 2006, 95, 147-152. | 1.1 | 35 |
| 46 | Adherence to treatment guidelines and survival for older patients with stage II or III colon cancer in Texas from 2001 through 2011. <i>Cancer</i> , 2018, 124, 679-687. | 2.0 | 35 |
| 47 | Angiogenesis in the Bone Marrow of Patients with Breast Cancer. <i>Clinical Cancer Research</i> , 2005, 11, 5396-5400. | 3.2 | 34 |
| 48 | Use of ACE Inhibitors and Angiotensin Receptor Blockers and Primary Breast Cancer Outcomes. <i>Journal of Cancer</i> , 2013, 4, 549-556. | 1.2 | 34 |
| 49 | Multigene Clinical Mutational Profiling of Breast Carcinoma Using Next-Generation Sequencing. <i>American Journal of Clinical Pathology</i> , 2015, 144, 713-721. | 0.4 | 34 |
| 50 | Breast Conservation in the Setting of Contemporary Multimodality Treatment Provides Excellent Outcomes for Patients with Occult Primary Breast Cancer. <i>Annals of Surgical Oncology</i> , 2015, 22, 90-95. | 0.7 | 34 |
| 51 | Functional consequence of the<i>MET-T</i>1010I polymorphism in breast cancer. <i>Oncotarget</i> , 2015, 6, 2604-2614. | 0.8 | 34 |
| 52 | Receptor Status Change From Primary to Residual Breast Cancer After Neoadjuvant Chemotherapy and Analysis of Survival Outcomes. <i>Clinical Breast Cancer</i> , 2015, 15, 153-160. | 1.1 | 33 |
| 53 | Mesothelin Expression and Survival Outcomes inÂTriple Receptor Negative Breast Cancer. <i>Clinical Breast Cancer</i> , 2013, 13, 378-384. | 1.1 | 32 |
| 54 | Burden of symptoms associated with development of metastatic bone disease in patients with breast cancer. <i>Supportive Care in Cancer</i> , 2016, 24, 3557-3565. | 1.0 | 32 |

| # | ARTICLE | IF | CITATIONS |
|----|---|-----|-----------|
| 55 | Guidelines for Guidelines: An Assessment of the American Society of Breast Surgeons Contralateral Prophylactic Mastectomy Consensus Statement. <i>Annals of Surgical Oncology</i> , 2017, 24, 1-2. | 0.7 | 32 |
| 56 | Acute myeloid leukemia and myelodysplastic syndrome after adjuvant chemotherapy: A population-based study among older breast cancer patients. <i>Cancer</i> , 2018, 124, 899-906. | 2.0 | 30 |
| 57 | Ductal Carcinoma In Situ and Margins $\geq 2\text{ mm}$. <i>Annals of Surgery</i> , 2019, 269, 150-157. | 2.1 | 29 |
| 58 | Efficacy and safety of the combination of metformin, everolimus and exemestane in overweight and obese postmenopausal patients with metastatic, hormone receptor-positive, HER2-negative breast cancer: a phase II study. <i>Investigational New Drugs</i> , 2019, 37, 345-351. | 1.2 | 28 |
| 59 | Impact of Delayed Neoadjuvant Systemic Chemotherapy on Overall Survival Among Patients with Breast Cancer. <i>Oncologist</i> , 2020, 25, 749-757. | 1.9 | 28 |
| 60 | Recurrence and survival among breast cancer patients achieving a pathological complete response to neoadjuvant chemotherapy. <i>Breast Cancer Research and Treatment</i> , 2015, 153, 417-423. | 1.1 | 27 |
| 61 | Neoadjuvant Chemotherapy does not Increase Complications in Oncoplastic Breast-Conserving Surgery. <i>Annals of Surgical Oncology</i> , 2019, 26, 2730-2737. | 0.7 | 27 |
| 62 | Estimating regimen-specific costs of chemotherapy for breast cancer: Observational cohort study. <i>Cancer</i> , 2016, 122, 3447-3455. | 2.0 | 23 |
| 63 | Clinicopathological and surgical factors associated with long-term survival in patients with HER2-positive metastatic breast cancer. <i>Breast Cancer Research and Treatment</i> , 2016, 159, 367-374. | 1.1 | 23 |
| 64 | EpCAM-independent isolation of circulating tumor cells with epithelial-to-mesenchymal transition and cancer stem cell phenotypes using ApoStream [®] in patients with breast cancer treated with primary systemic therapy. <i>PLoS ONE</i> , 2020, 15, e0229903. | 1.1 | 23 |
| 65 | Initiation of and adherence to tamoxifen and aromatase inhibitor therapy among elderly women with ductal carcinoma in situ. <i>Cancer</i> , 2017, 123, 940-947. | 2.0 | 22 |
| 66 | Clinical outcomes based on multigene profiling in metastatic breast cancer patients. <i>Oncotarget</i> , 2016, 7, 76362-76373. | 0.8 | 22 |
| 67 | Status of the anaplastic lymphoma kinase (ALK) gene in inflammatory breast carcinoma. <i>SpringerPlus</i> , 2013, 2, 409. | 1.2 | 21 |
| 68 | Combining Clinical and Pathologic Staging Variables Has Prognostic Value in Predicting Local-regional Recurrence Following Neoadjuvant Chemotherapy for Breast Cancer. <i>Annals of Surgery</i> , 2017, 265, 574-580. | 2.1 | 21 |
| 69 | Association of Body Mass Index Changes during Neoadjuvant Chemotherapy with Pathologic Complete Response and Clinical Outcomes in Patients with Locally Advanced Breast Cancer. <i>Journal of Cancer</i> , 2015, 6, 310-318. | 1.2 | 20 |
| 70 | Clinical Outcomes Associated with Drug-Drug Interactions of Oral Chemotherapeutic Agents: A Comprehensive Evidence-Based Literature Review. <i>Drugs and Aging</i> , 2019, 36, 341-354. | 1.3 | 20 |
| 71 | Delayed initiation of adjuvant chemotherapy in older women with breast cancer. <i>Cancer Medicine</i> , 2020, 9, 6961-6971. | 1.3 | 20 |
| 72 | Barriers to the Use of Breast Cancer Risk Reduction Therapies. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2015, 13, 927-935. | 2.3 | 19 |

| # | ARTICLE | IF | CITATIONS |
|----|--|------|-----------|
| 73 | High HER2/Centromeric Probe for Chromosome 17 Fluorescence In Situ Hybridization Ratio Predicts Pathologic Complete Response and Survival Outcome in Patients Receiving Neoadjuvant Systemic Therapy With Trastuzumab for HER2-Overexpressing Locally Advanced Breast Cancer. <i>Oncologist</i> , 2016, 21, 21-27. | 1.9 | 19 |
| 74 | Outcomes in patients with early-stage breast cancer who underwent a 21-gene expression assay. <i>Cancer</i> , 2017, 123, 2422-2431. | 2.0 | 19 |
| 75 | Differences in Gene and Protein Expression and the Effects of Race/Ethnicity on Breast Cancer Subtypes. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2014, 23, 316-323. | 1.1 | 18 |
| 76 | Nomogram to predict pathologic complete response in HER2-positive breast cancer treated with neoadjuvant systemic therapy. <i>British Journal of Cancer</i> , 2017, 116, 509-514. | 2.9 | 18 |
| 77 | Breast cancer, neoadjuvant chemotherapy and residual disease. <i>Clinical and Translational Oncology</i> , 2010, 12, 461-467. | 1.2 | 17 |
| 78 | Complications associated with erythropoietin-stimulating agents in patients with metastatic breast cancer. <i>Cancer</i> , 2011, 117, 3641-3649. | 2.0 | 16 |
| 79 | American Society of Breast Surgeons™ Practice Patterns After Publication of the SSO-ASTRO-ASCO DCIS Consensus Guideline on Margins for Breast-Conserving Surgery With Whole-Breast Irradiation. <i>Annals of Surgical Oncology</i> , 2018, 25, 2965-2974. | 0.7 | 16 |
| 80 | Use of Biosimilar Medications in Oncology. <i>JCO Oncology Practice</i> , 2022, 18, 177-186. | 1.4 | 15 |
| 81 | Short-term mortality in older patients treated with adjuvant chemotherapy for early-stage breast cancer. <i>Breast Cancer Research and Treatment</i> , 2016, 157, 339-350. | 1.1 | 14 |
| 82 | Impact of the timing of hepatitis B virus identification and anti-hepatitis B virus therapy initiation on the risk of adverse liver outcomes for patients receiving cancer therapy. <i>Cancer</i> , 2017, 123, 3367-3376. | 2.0 | 13 |
| 83 | Racial and Socioeconomic Disparities in Breast Cancer Outcomes within the AJCC Pathologic Prognostic Staging System. <i>Annals of Surgical Oncology</i> , 2022, 29, 686-696. | 0.7 | 11 |
| 84 | Phase Ib Dose-escalation/Expansion Trial of Ribociclib in Combination With Everolimus and Exemestane in Postmenopausal Women with HR+, HER2+ Advanced Breast Cancer. <i>Clinical Cancer Research</i> , 2020, 26, 6417-6428. | 3.2 | 11 |
| 85 | Everolimus in the treatment of hormone receptor-positive breast cancer. <i>Expert Opinion on Investigational Drugs</i> , 2012, 21, 1835-1843. | 1.9 | 10 |
| 86 | Bisphosphonates and pathologic complete response to taxane- and anthracycline-based neoadjuvant chemotherapy in patients with breast cancer. <i>Cancer</i> , 2012, 118, 326-332. | 2.0 | 10 |
| 87 | Survival in older women with early stage breast cancer receiving low-dose bisphosphonates or denosumab. <i>Cancer</i> , 2020, 126, 3929-3938. | 2.0 | 10 |
| 88 | New drugs, new knowledge, new targets. <i>Nature Reviews Clinical Oncology</i> , 2013, 10, 75-76. | 12.5 | 9 |
| 89 | Survival by Hispanic ethnicity among patients with cancer participating in SWOG clinical trials. <i>Cancer</i> , 2018, 124, 1760-1769. | 2.0 | 9 |
| 90 | Complications of Contralateral Prophylactic Mastectomy: Do They Delay Adjuvant Therapy?. <i>Plastic and Reconstructive Surgery</i> , 2020, 146, 945-953. | 0.7 | 9 |

| # | ARTICLE | IF | CITATIONS |
|-----|---|-----|-----------|
| 91 | Incremental Cancer Detection of Locoregional Restaging with Diagnostic Mammography Combined with Whole-Breast and Regional Nodal Ultrasound in Women with Newly Diagnosed Breast Cancer. <i>Academic Radiology</i> , 2017, 24, 191-199. | 1.3 | 8 |
| 92 | Delays in Adjuvant Chemotherapy Among Breast Cancer Patients: An Unintended Consequence of Breast Surgery?. <i>Annals of Surgical Oncology</i> , 2018, 25, 1786-1787. | 0.7 | 8 |
| 93 | ASCO Resource-Stratified Guidelines: Methods and Opportunities. <i>Journal of Global Oncology</i> , 2018, 4, 1-8. | 0.5 | 7 |
| 94 | Diagnosis of brain metastases in breast cancer patients resulting from neurological symptoms. <i>Clinical Neurology and Neurosurgery</i> , 2018, 173, 61-64. | 0.6 | 7 |
| 95 | Adjuvant tamoxifen adherence in men with early-stage breast cancer. <i>Cancer</i> , 2021, , . | 2.0 | 7 |
| 96 | Two Birds With One Stone: Octreotide Treatment for Acromegaly and Breast Cancer. <i>Journal of Clinical Oncology</i> , 2013, 31, e398-e400. | 0.8 | 6 |
| 97 | Granulocyte growth factor use in elderly patients with non-Hodgkin's lymphoma in the United States: adherence to guidelines and comparative effectiveness. <i>Supportive Care in Cancer</i> , 2016, 24, 2695-2706. | 1.0 | 6 |
| 98 | Comparative Analysis of Proposed Strategies for Incorporating Biologic Factors into Breast Cancer Staging. <i>Annals of Surgical Oncology</i> , 2020, 27, 2229-2237. | 0.7 | 6 |
| 99 | Real-World Patterns of Everolimus Use in Patients with Metastatic Breast Cancer. <i>Oncologist</i> , 2020, 25, 937-942. | 1.9 | 6 |
| 100 | Association of Medicaid Expansion With Mortality Disparity by Race and Ethnicity Among Patients With De Novo Stage IV Breast Cancer. <i>JAMA Oncology</i> , 2022, 8, 863. | 3.4 | 6 |
| 101 | Anthracycline or trastuzumab-related cardiotoxicity: do we have a predictive biomarker?. <i>Biomarkers in Medicine</i> , 2016, 10, 315-328. | 0.6 | 5 |
| 102 | Adjuvant HER2-Targeted Therapy Update in Breast Cancer: Escalation and De-escalation of Therapy in 2018. <i>Current Breast Cancer Reports</i> , 2018, 10, 296-306. | 0.5 | 5 |
| 103 | Staging for Breast Cancer Patients Receiving Neoadjuvant Chemotherapy: Utility of Incorporating Biologic Factors. <i>Annals of Surgical Oncology</i> , 2020, 27, 359-366. | 0.7 | 5 |
| 104 | All HER2-Positive Tumors are not Created Equal. <i>Annals of Surgical Oncology</i> , 2017, 24, 3471-3474. | 0.7 | 4 |
| 105 | Impact of SSO-ASTRO's No Ink on Tumor Guidelines on Reexcision Rates among Older Breast Cancer Patients. <i>Annals of Surgical Oncology</i> , 2021, 28, 3703-3713. | 0.7 | 4 |
| 106 | A Randomized Phase II Study of Sequential Eribulin Versus Paclitaxel Followed by FAC/FEC as Neoadjuvant Therapy in Patients with Operable HER2-Negative Breast Cancer. <i>Oncologist</i> , 2021, 26, e230-e240. | 1.9 | 3 |
| 107 | Identification of risk factors for central nervous system metastasis in patients with breast cancer with neurologic symptoms. <i>Cancer</i> , 2020, 126, 3456-3463. | 2.0 | 3 |
| 108 | Movement Through Chemotherapy Delay to Initiation Among Breast Cancer Patients: A Qualitative Analysis. <i>Patient Preference and Adherence</i> , 2022, Volume 16, 749-759. | 0.8 | 3 |

| # | ARTICLE | IF | CITATIONS |
|-----|---|-----|-----------|
| 109 | Survival outcomes following pregnancy or assisted reproductive technologies after breast cancer: A population-based study. <i>Cancer</i> , 2022, 128, 3243-3253. | 2.0 | 3 |
| 110 | Tamoxifen therapy for patients with breast cancer. <i>Lancet</i> , The, 2013, 381, 2077-2078. | 6.3 | 2 |
| 111 | Association Between Quality of Care for Breast Cancer and Health Insurance Exchange Coverage. <i>JAMA Oncology</i> , 2017, 3, 1425. | 3.4 | 2 |
| 112 | Hospitalization by cytotoxic chemotherapy regimen among older women with stage IV breast cancer. <i>Cancer</i> , 2018, 124, 4685-4691. | 2.0 | 2 |
| 113 | The Devastating Legacy of Breast Cancer Death in Sub-Saharan Africa—Maternal Orphans and a Cycle of Disadvantage. <i>JAMA Oncology</i> , 2021, 7, 197. | 3.4 | 2 |
| 114 | Outcomes of Post Mastectomy Radiation Therapy in Patients Receiving Axillary Lymph Node Dissection After Positive Sentinel Lymph Node Biopsy. <i>International Journal of Radiation Oncology Biology Physics</i> , 2016, 96, 637-644. | 0.4 | 1 |
| 115 | Extended adjuvant therapy in patients with HER2-positive breast cancer: some answers, even more questions. <i>Lancet Oncology</i> , The, 2017, 18, 1568-1569. | 5.1 | 1 |
| 116 | Adjuvant bisphosphonates in breast cancer: has the time come?. <i>Breast Cancer Management</i> , 2013, 2, 327-337. | 0.2 | 0 |